

EBAMed, Swiss-Italian Company, raises EUR 14.35 Million in Series A Funding to develop its novel image guidance system for the non-invasive treatment of Ventricular Tachycardia through Proton Therapy

GENEVA, June 27, 2023 --EBAMed SA, a Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias, announced today the raising of 14.35 M € in Series A Funding to accelerate the development of an innovative device to advance cardiac radiation ablation therapy. The financing round was led by Panakès Partners, a venture capital firm with headquarters in Milan, together with the EIC Fund, Swiss EFI Lake Geneva Ventures, LIFTT Venture Capital Italia, and OCCIDENT. The round was also supported by existing investors, including Mayo Clinic.

The fund will be used to bring EBAMed's CardioKit system - a device that automatically adjusts cardiac radiation ablation systems for cardiac motion and increases external beam delivery precision – up to the completion of its First in Human trials.

The development of a radiation therapy approach, combined with a unique motion monitoring and gating solution, will fill an important need for alternatives to either drug therapy or catheter-based ablation, and for reduced radiation of healthy myocardium.

"I am thrilled by the successful completion of our Series A financing, which will enable us to advance the development of our Image Guidance System", commented **Giovanni Leo**, Partner at EFI Lake Geneva Ventures I, co-founder, and Chairman of EBAMed SA. "I am especially excited by the recognition of our potential by investors in Italy. Headquartered in Switzerland, we are a Swiss/Italian reality, with Italian co-founders and a strong mix of Italian and Swiss directors on the Board. This allows us to derive synergies from a large, diverse talent pool. What's more, with the recent opening of a subsidiary in Milan, we are in a strong position to expand our operations into Italy."

Barbara Castellano, Partner of Panakès Partners, added: "Cardiac arrhythmias are an increasing health problem worldwide and therapeutic options for ventricular tachycardia patients remain limited and suboptimal. Radio ablation using protons, combining respiratory and cardiac gating, represents a new precision medicine approach to treat this difficult patient population. We are extremely impressed by the EBAMed team and are very excited to support the company's development of the CardioKit system."

Marina Izzo, Chief Executive Officer of EBAMed, commented: "It is our mission to optimize radio therapy for Cardiac Indications. With recent exciting developments towards compensation for cardiorespiratory movements, we believe our technology has the potential to revolutionize the treatment of cardiac arrhythmias. The new funding will help us bring our groundbreaking technology to patients in need and become a key component in the future non-invasive ablation treatment pathway for life-threatening arrhythmias."

About EBAMed SA

EBAMed is a private medical device company developing a novel treatment system to monitor and react to heart movement during cardiac radioablation procedures. The aim is to reduce the volume of healthy heart exposed to more than 20 Gray of Protons/Photons during cardiac radio ablation procedures, thereby maximizing long-term safety for patients. Learn more at <http://www.eba-med.com> or follow us on [LinkedIn](#).

About Panakès Partners

Panakès Partners is the leading Italian Venture capital firm in the Life Sciences sector, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, aiming to improve the lives of people around the world. Panakès, founded in 2015 has €250 million under management. www.panakes.it.

About EIC Fund

The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance.

The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialization of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.

The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.

About Efficient Frontier Investing

EFI Lake Geneva Ventures is Geneva-based seed and early-stage investment strategy with the mission to foster innovation in Technology, Life Sciences and MedTech. In partnership with the Swiss network of incubators and with close proximity to universities and research centers, it benefits from early access to the best innovations and cherry-pick the most attractive and innovative opportunities in the market.

About LIFTT

LIFTT is an Italian Venture Capital chaired by the scientist-entrepreneur Stefano Buono. Operating in every industry with a focus on deep-tech, to date it has completed 36 investments in innovative start-ups. While generating value for its shareholders, LIFTT supports the creation of businesses, development, employment, and economic growth, through the implementation of an ethical and transparent governance model. To learn more, please visit www.lifft.com

About OCCIDENT

OCCIDENT is an international venture capital investor with offices in Zug and Munich, is owner-managed and invests own wealth. Its aim is to make a positive contribution to society through sustainable and meaningful investments. OCCIDENT invests in innovative deep tech start-ups with excellent technologies in the fields of life sciences, digital and high-tech with broad

application possibilities and the potential for further value-generating developments. The geographic focus is Germany and Switzerland. The preferred stage for initial financing is from seed rounds or later and from 0.5 million euros. OCCIDENT distinguishes itself in particular by its in-depth knowledge of the technology and the versatile support offered to its portfolio companies by its competent team of experts. For more information, please visit www.occident.group.



This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 954783.

For further information please contact:

Marina Izzo
C.E.O.

marina.izzo@eba-med.com

+41 77 5121686

EBAMed SA
Campus Biotech Innovation Park
Avenue de Sécheron 15
CH-1202 Geneva
Switzerland